Adaptation of TeamBest FDG Technology Applied to Novel Prostate Cancer Specific Tracers

点击翻译按钮获取中文摘要

The usefulness of positron emission tomography (PET) imaging is best demonstrated by current data suggesting that in as many as one-third to one-half of cancer cases, physicians who do not have access to PET may be choosing the wrong management or treatment strategy for their patients. PET imaging relies on radiopharmaceuticals label with a radioactive element that decays through positron emmission. By far the most common radioisotope used for PET imagine is fluorine-18. The isotope fluorine-18 decays rapidly, with a half-life of 110 minutes. Such a short half-life makes shipping the radiotracers long distances expensive and often impractical. Thus synthesis of the radiopharmaceutical is ideally performed at the source of of fluorine 18. Although 96% of PET scans are perfomed with fluorodeoxyglucose (FDG), this particular radiotracer is non-specific and not ideal when monitior specific types of cancers. A up-and-coming PET approach is the use of Prostate specific membrane antigen imaging (PSMA). PSMA PET is very sensitive for detecting prostate cancer and is currently used in patients with new diagnosis of high-risk prostate cancer and those with biochemical recurrence. Thus, a reliable and expedient synthesis method of PSMA related PET agents is of high interest to the medical industry.